Viyash Scientific Ltd
Viyash Scientific Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #70 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
API business to achieve double-digit growth next year, driven by approvals in human health APIs and stepped-up animal health API sales. EBITDA growth target: Aim to reach INR1,000 crores in 2-3 years, with internal target around FY27-FY28.
From Viyash Scientific Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- API business to achieve double-digit growth next year, driven by approvals in human health APIs and stepped-up animal health API sales.
- Animal health business growing after 5 years of stagnation, increasing from ~INR350 crores to INR400 crores, with strong growth expected.
- Formulation business growing 18% in FY26, with focus on complex products and internal APIs supporting sustainable margin expansion.
- CDMO business expected to grow 30-40% next year, with 8-10 innovators engaged and approvals for new products coming.
2 more points from Viyash Scientific Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Viyash Scientific Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- There is ongoing and planned capex for capacity expansion, especially in Viyash's manufacturing facilities, awaiting approvals to realize further synergies (mentioned on Page 13).
- Significant investment is planned in R&D, particularly in finished product formulation for both human health and animal health sectors, focusing on complex molecules (Page 14).
- Expansion of R&D team and resources, especially for animal health formulation, accompanied by increased capex (Page 17).
- Building and investing in an oncology R&D lab for new product development (Page 8).
2 more points from Viyash Scientific Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Viyash Scientific Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Viyash Scientific Ltd's call on order book
Create a free account to keep reading this call
Viyash Scientific Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹920 Cr, net profit ₹66 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Viyash Scientific's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Guj. Themis Bio. (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Viyash Scientific Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Viyash Scientific Ltd Q4 FY26 results?
API business to achieve double-digit growth next year, driven by approvals in human health APIs and stepped-up animal health API sales. EBITDA growth target: Aim to reach INR1,000 crores in 2-3 years, with internal target around FY27-FY28.
What is Viyash Scientific Ltd share price analysis?
Viyash Scientific Ltd currently shows a neutral. The stock trades at a P/E of 50.8 with a market cap of ₹11,246 Cr. Investors should review the full earnings analysis for detailed insights.
Is Viyash Scientific Ltd planning capital expenditure?
There is ongoing and planned capex for capacity expansion, especially in Viyash's manufacturing facilities, awaiting approvals to realize further synergies (mentioned on Page 13).
Keep Viyash Scientific Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.